Antipsychotics in child and adolescent patients with major depressive disorder: A retrospective analysis of prescribing patterns.

Autor:	Dauchot D; Psychiatric Pharmacy Practice Resident, Department of Pharmacy, University of Kansas Health System, Kansas City, Kansas, dbdauchot@me.com., Rettey S; Psychiatric Clinical Pharmacist, Department of Pharmacy, University of Kansas Health System, Kansas City, Kansas, suzannerettey@gmail.com., Melton BL; Associate Professor, Associate Chair, Department of Pharmacy Practice, The University of Kansas School of Pharmacy, Lawrence, Kansas, bmelton2@kumc.edu., Moeller KE; Psychiatric Pharmacy Practice Resident, Department of Pharmacy, University of Kansas Health System, Kansas City, Kansas, dbdauchot@me.com.; Psychiatric Clinical Pharmacist, Department of Pharmacy, University of Kansas Health System, Kansas City, Kansas, suzannerettey@gmail.com.; Associate Professor, Associate Chair, Department of Pharmacy Practice, The University of Kansas School of Pharmacy, Lawrence, Kansas, bmelton2@kumc.edu.
Jazyk:	angličtina
Zdroj:	The mental health clinician [Ment Health Clin] 2024 Feb 01; Vol. 14 (1), pp. 10-16. Date of Electronic Publication: 2024 Feb 01 (Print Publication: 2024).
DOI:	10.9740/mhc.2024.02.010
Abstrakt:	Introduction: Depression rates in children/adolescents in the United States have increased in the last 10 years. Fluoxetine and escitalopram are the only 2 antidepressants approved for the treatment of major depression disorder (MDD) in children/adolescents. In adults, some antipsychotics are approved for augmented treatment of MDD. However, there is limited research on antipsychotic augmentation in child/adolescent MDD. Methods: This retrospective chart review evaluated antipsychotic prescribing for MDD in hospitalized patients aged 4 to 17 years to determine the frequency of prescribing antipsychotics for MDD and what factors influence the addition of an antipsychotic. For inclusion, patients were diagnosed with MDD and not on an antidepressant or antipsychotic before admission. Binomial logistic regression was used to analyze variables with prescribed antipsychotics as the dependent variable. Results: There were 6.8% of patients prescribed an antipsychotic. Binomial logistic regression analysis found that increased age (odds ratio [OR] 1.28; 95% CI = 1.045, 1.568; P = .017) and multiple admissions within 1 year (OR 3.277; 95% CI = 2.283, 4.705; P < .001) were associated with the use of antipsychotics in patients with MDD. Posttraumatic stress disorder and disruptive mood dysregulation disorder were also associated with the use of antipsychotics. Discussion: Careful consideration should be taken when using off-label antipsychotics in children due to limited studies on efficacy. Future research is warranted to assess the efficacy and safety of these agents in children and adolescents. Competing Interests: Disclosures: The authors have no conflicts of interest to disclose. (© 2024 AAPP. The Mental Health Clinician is a publication of the American Association of Psychiatric Pharmacists.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu